Showing results (191-200 of 223) with videos related to

Sort By:
Pageof 23
Neurological Research and Practice|July 31, 2024
Multidisciplinary lifestyle interventions for neurological disorders during the Silent phase (MINDS) study: a multi-omics randomized controlled trial protocolSara Taylor, Seerat Sachdeva, Sandra Darling, et al.
Neurology|October 24, 2019
Evaluation of multiple sclerosis disability outcome measures using pooled clinical trial dataMyla D Goldman, Nicholas G LaRocca, Richard A Rudick, et al.
Annals of Neurology|March 10, 2011
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteriaChris H Polman, Stephen C Reingold, Brenda Banwell, et al.
Neurology and Therapy|July 13, 2025
Five-Year Safety and Efficacy Outcomes with Ofatumumab in Patients with Relapsing Multiple SclerosisStephen L Hauser, Jeffrey A Cohen, Jérôme de Sèze, et al.
Neurology|September 4, 2016
Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β-1a in MSDouglas L Arnold, Elizabeth Fisher, Vesna V Brinar, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 5, 2025
Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Final analysis of the DAYBREAK open-label extension trialKrzysztof W Selmaj, Lawrence Steinman, Giancarlo Comi, et al.
Inflammatory Bowel Diseases|February 12, 2026
Integrated long-term safety of 10-year ozanimod treatment: results from clinical trials in patients with moderate-to-severe ulcerative colitis or relapsing multiple sclerosisDavid T Rubin, Silvio Danese, Hiroshi Nakase, et al.
JAMA Neurology|September 16, 2024
Differential Diagnosis of Suspected Multiple Sclerosis in Pediatric and Late-Onset Populations: A ReviewLe H Hua, Andrew J Solomon, Silvia Tenembaum, et al.
Neurology|August 25, 2017
Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findingsAlasdair J Coles, Jeffrey A Cohen, Edward J Fox, et al.
Lancet (London, England)|November 6, 2012
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trialAlasdair J Coles, Cary L Twyman, Douglas L Arnold, et al.
Pageof 23